stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Gratuito - Play StoreApp Store
InstallareInstallare
logo
Relay Therapeutics IncRLAY
$17.813.07%0.53

Relay Therapeutics Inc (RLAY)

Date: 2026-11-03 16:00O: 17.52H: 18.01L: 17.28C: 17.81Vol: 1.197M
Precedente Chiudi:
$17.28
Aprire:
$17.52
Volume 24 ore:
1,201,372
Volume relativo:
0.54
Capitalizzazione di mercato:
$3.90B
Reddito:
$10.68M
Utile/perdita netta:
-$272.71M
Rapporto P/E:
-
EPS:
-$1.57
Flusso di cassa netto:
-$213.38M
1W Prestazione:
-5.47%
1M Prestazione:
-6.07%
6M Prestazione:
+40.02%
1Y Prestazione:
+156.63%
Intervallo 1D:
$17.28$18.01
Intervallo di 1 settimana:
$17.24$20.20
Portata 52W:
$5.95$21.27

Profilo aziendale di Relay Therapeutics Inc (RLAY)

Nome
Relay Therapeutics Inc
Settore
Healthcare
Industria
Biotechnology
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE, USA
Dipendente
192
X
-
Prossima data di guadagno
2026-11-05
Ultimi documenti SEC
SEC
Discussioni di RLAY su X
X

 

Cap. di mercato

 

Reddito

 

Reddito netto

 

Flusso di cassa

 

EPS

 

Relay Therapeutics Inc Azioni (RLAY) Upgrade e downgrade

DataAzioneAnalistaModifica della valutazione
2026-07-16IniziatoCanaccord GenuityBuy
2026-07-08IniziatoJP MorganOverweight
2026-01-26AggiornamentoOppenheimerPerform → Outperform
2025-12-12AggiornamentoWells FargoEqual Weight → Overweight

Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari

PeriodoAndamentoFY 2025FY 2024FY 2023FY 2022FY 2021
Data di fine periodo2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue USD (M)15.3610.0125.551.3830.29
Operating expenses USD (M)318.09382.48398.55300.66367.73
Operating income USD (M)-302.74-372.47-373.00-299.28-364.70
Income before tax USD (M)--25.551.38-363.87
Income tax expense USD (M)0.000.000.000.000.00
Net income USD (M)-276.48-337.71-341.97-290.51-363.87
Basic EPS USD/shares-1.61-2.36-2.79-2.59-
Diluted EPS USD/shares-1.61-2.36-2.79-2.59-
Basic weighted shares shares (M)171.59142.87122.58112.23-
Diluted weighted shares shares (M)---112.23-

Relay Therapeutics Inc Azioni (RLAY) insider trading

  • President, R&D
    Transazione
    Sale
    Costo
    $18.62
    #Azioni
    2,252
    Valore ($)
    41,932
    #Azioni Totale
    396,878
  • Rahmer PeterOct 28 '26
    See remarks
    Transazione
    Sale
    Costo
    $18.62
    #Azioni
    753
    Valore ($)
    14,021
    #Azioni Totale
    222,904
  • Chief Financial Officer
    Transazione
    Sale
    Costo
    $18.62
    #Azioni
    1,469
    Valore ($)
    27,353
    #Azioni Totale
    103,665
  • Patel SanjivOct 07 '26
    President and CEO
    Transazione
    Sale
    Costo
    $18.10
    #Azioni
    48,199
    Valore ($)
    872,402
    #Azioni Totale
    471,301
  • SANJIV PATELOct 07 '26
    Director
    Transazione
    Proposed Sale
    Costo
    $18.74
    #Azioni
    96,401
    Valore ($)
    1,806,555
    #Azioni Totale
    0
  • Officer
    Transazione
    Proposed Sale
    Costo
    $19.39
    #Azioni
    93,153
    Valore ($)
    1,806,237
    #Azioni Totale
    0
  • Chief Financial Officer
    Transazione
    Sale
    Costo
    $18.59
    #Azioni
    17,717
    Valore ($)
    329,322
    #Azioni Totale
    105,134
  • President, R&D
    Transazione
    Sale
    Costo
    $18.97
    #Azioni
    8,530
    Valore ($)
    161,814
    #Azioni Totale
    399,130
  • Patel SanjivSep 08 '26
    President and CEO
    Transazione
    Sale
    Costo
    $18.94
    #Azioni
    48,199
    Valore ($)
    912,889
    #Azioni Totale
    519,500
  • Chief Financial Officer
    Transazione
    Sale
    Costo
    $18.94
    #Azioni
    17,717
    Valore ($)
    335,560
    #Azioni Totale
    122,851
Commercio internoRelazioneDataTransazioneCosto#AzioniValore ($)#Azioni Totale
Bergstrom Donald APresident, R&DOct 28 '26Sale$18.622,25241,932396,878
Rahmer PeterSee remarksOct 28 '26Sale$18.6275314,021222,904
Catinazzo ThomasChief Financial OfficerOct 28 '26Sale$18.621,46927,353103,665
Patel SanjivPresident and CEOOct 07 '26Sale$18.1048,199872,402471,301
SANJIV PATELDirectorOct 07 '26Proposed Sale$18.7496,4011,806,5550
THOMAS CATINAZZOOfficerOct 06 '26Proposed Sale$19.3993,1531,806,2370
Catinazzo ThomasChief Financial OfficerOct 06 '26Sale$18.5917,717329,322105,134
Bergstrom Donald APresident, R&DSep 08 '26Sale$18.978,530161,814399,130
Patel SanjivPresident and CEOSep 08 '26Sale$18.9448,199912,889519,500
Catinazzo ThomasChief Financial OfficerSep 08 '26Sale$18.9417,717335,560122,851

Relay Therapeutics Inc Borsa (RLAY) Ultime notizie

Nov 02, 2026
Nov 02, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 30, 2026
Oct 24, 2026
Oct 24, 2026
Oct 15, 2026
Oct 15, 2026
Oct 14, 2026
Oct 14, 2026
Oct 13, 2026
Oct 13, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 08, 2026
Oct 07, 2026
Oct 07, 2026
Oct 06, 2026
Oct 06, 2026
Sep 23, 2026
Sep 23, 2026
Sep 21, 2026
Sep 21, 2026
Sep 10, 2026
Sep 10, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 09, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 08, 2026
Sep 06, 2026
Sep 06, 2026
Sep 02, 2026
Sep 02, 2026
Sep 02, 2026
Sep 02, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Sep 01, 2026
Aug 29, 2026
Aug 29, 2026
Aug 28, 2026
Aug 28, 2026
Aug 28, 2026
Aug 28, 2026
Aug 28, 2026
Aug 28, 2026

Simile a RLAY